Indoco Remedies gets USFDA nod for Parkinson’s disease treatment drug

PTI | Updated on October 08, 2019 Published on October 07, 2019


New Delhi, October 7 Drug firm Indoco Remedies on Monday said it has received approval from the US health regulator for Rasagiline tablets, used for the treatment of Parkinson’s disease.

The company has received the final nod for its abbreviated new drug application (ANDA) for Rasagiline tablets in the strengths of 0.5 mg and 1 mg from the United States Food and Drug Administration (USFDA), Indoco Remedies said in a regulatory filing.

Quoting IMS 2018 data, Indoco Remedies said the market size of this product in the US is USD 105 million.

“This is the first ANDA approval for Indoco after receipt of warning letter in March 2017 for Goa plant II and III. The company has 32 ANDAs pending for approval for different dosage forms from this site,” Indoco Remedies Managing Director Aditi Kare Panandikar said.

Published on October 07, 2019
  1. Comments will be moderated by The Hindu Business Line editorial team.
  2. Comments that are abusive, personal, incendiary or irrelevant cannot be published.
  3. Please write complete sentences. Do not type comments in all capital letters, or in all lower case letters, or using abbreviated text. (example: u cannot substitute for you, d is not 'the', n is not 'and').
  4. We may remove hyperlinks within comments.
  5. Please use a genuine email ID and provide your name, to avoid rejection.